- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Gynecologic Cancers | Clinical
FDA Accepts BLA For Balstilimab To Treat Recurrent or Metastatic Cervical Cancer
June 17, 2021
The FDA has accepted the biologics license application for the anti-PD-1 antibody drug balstilimab for the treatment of recurrent of metastatic cervical cancer with disease progression on or after chemotherapy.
Advancing the Treatment of Cervical and Endometrial Cancers
June 15, 2021
In season 2, episode 6 of Targeted Talks, Alexander B. Olawaiye, MD leads a discussion with Haider S. Mahdi, MD, about the modern approaches to treating cervical and endometrial cancers.
High-Grade Ovarian Cancer Shows Survival Gap Between HR-Deficient and Proficient BRCA+ Tumors
June 11, 2021
In an interview with Targeted Oncology, held during the 2021 ASCO Annual Meeting, Travis Sims, MD, MPH, discussed the treatment of HRD-positive ovarian cancer and the retrospective analysis of HRD status and its impact of survival outcomes for this patient population.
Pertuzumab Plus Trastuzumab Demonstrates Clinical Activity in ERBB2/ERBB3+ Uterine Cancer
June 07, 2021
In patients with ERBB2/ERBB3-expressed, mutated, or -amplified uterine cancer, the combination of pertuzumab and trastuzumab led to a 37% disease control rate, according to results from the Targeted Agent Profiling and Utilization Registry study.
Adjuvant Chemotherapy Does Not Improve 5-Year Overall Survival in Locally Advanced Cervical Cancer
June 03, 2021
In women with locally advanced cervical cancer, administering adjuvant chemotherapy following standard cisplatin-based chemoradiation did not improve survival outcomes, according to findings from the phase 3 OUTBACK trial.
Clinical Trials Explore Novel Targets for Cervical Cancer to Enhance Treatment Efforts
May 27, 2021
In an interview with Targeted Oncology following the medical conference presentation, Ritu Salani, MD, expanded on the role biomarkers play in the treatment of cervical cancer, how this testing looks in the everyday clinics, and how it can potentially change pending competition of ongoing clinical trials.
Correlation Between Screening Guidelines and Decline in HPV-Related Cervical Cancer May Useful for Other Cancers
May 19, 2021
For the past 17 years, HPV-related cervical cancer has been declining, however, other tumors related to the virus continue to remain steady.
Investigating Low Survival Rates in Patients With Vulvar/Vaginal Melanomas
May 12, 2021
Annelise Wilhite, MD, discusses a clinical investigation of survival in patients with vulvar/vaginal melanomas.
FDA Grants Priority Review to Pembrolizumab Plus Lenvatinib in Advanced RCC and Endometrial Cancer
May 06, 2021
The FDA has granted priority review to 2 supplemental new drug applications for the combination use of pembrolizumab and lenvatinib.
Niraparib Improves PFS in Platinum-Sensitive Ovarian Cancer
May 03, 2021
In an interview with Targeted Oncology, Ursula A. Matulonis, MD, discusses results from further follow-up of patients with ovarian cancer treated in the ENGOT-OV16/NOVA.